Moderna (MRNA) posts a wider loss and cuts guidance as Covid vaccine sales drop. Its adjusted EPS came in at -$9.53 versus an estimated -$2.01 and revenue came in at $1.83B versus an estimated $1.33B. Moderna CFO Jamey Mock joins Oliver Renick to give an overview of the company. He talks about how MRNA sees at least $6B of Covid-19 vaccine sales in 2023. MRNA expects 50M doses in the U.S. this fall, which was previously estimated at 50M-100M doses. Mock then goes over what’s in the pipeline for MRNA. Tune in to find out more about the stock market today.
Market On Close
02 Nov 2023
SHARE
Market On Close
02 May 2024
Morning Trade Live
06 May 2024
Market On Close
10 Apr 2024
Market On Close
13 May 2024
Morning Trade Live
14 Feb 2024
Morning Trade Live
28 Mar 2024